Zurich-Schlieren, March 15, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin ®  therapeutics* to treat serious diseases, today published its audited Financial Results for 2018 and the company’s 2018 Annual Report.

Company to highlight the progress on its clinical DARPin® compounds, discuss MP0310 in its strategic partnership with Amgen and update on the initiation of a research project to explore DARPin® molecules targeting peptide MHC complexes supported by Gilead Zurich-Schlieren, March 11, 2019. 

Company positioned for growth following positive phase 3 abicipar data and validation of DARPin ®  platform through Amgen collaboration Research & Development: MP0310: Molecular Partners and Amgen announced strategic collaboration for clinical development and commercialization of lead IO candidate

Company to highlight recent progress on clinical DARPin ®  compounds, its oncology research strategy and to discuss the strategic collaboration with Amgen on MP0310 Zurich-Schlieren, January 7, 2019.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin ®

Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin ®  Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE ®  Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products   ZURICH-SCHLIEREN, SWITZERLAND

Zurich-Schlieren and New York, December 6, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin ®  therapeutics* to treat serious diseases, today announces the continued progress of its pipeline of proprietary therapeutic product

Zurich-Schlieren, November 6, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin ®  therapeutics* to treat serious diseases, today announced that the company plans to participate in several upcoming scientific conferences in November

Research & Development: MP0250 in multiple myeloma: Clinical trial ongoing with dose set at 8mg/kg every 3 weeks in combination with bortezomib/dexamethasone. Durable responses were seen in patients who came from proteasome inhibitor (PI) based pretreatment, suggesting that MP0250 might be capable

Zurich-Schlieren, October 29, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin ®  therapeutics* to treat serious diseases, today announced that the phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related

Promising initial data from MP0250 combination with bortezomib (Velcade ® ) in phase 2 study in multiple myeloma: Five of eight evaluable patients achieved an objective response with median time of treatment for responding patients of 22.5 weeks. MP0250 combination with osimertinib (Tagrisso ® ) in